- Joined
- Dec 3, 2017
- Messages
- 25,194
- Reaction score
- 15,431
- Gender
- Male
- Political Leaning
- Progressive
https://www.utsouthwestern.edu/newsroom/articles/year-2018/dna-vaccine-alzheimers.html
DALLAS – Nov. 20, 2018 – A DNA vaccine tested in mice reduces accumulation of both types of toxic proteins associated with Alzheimer’s disease, according to research that scientists say may pave the way to a clinical trial.
A new study by UT Southwestern’s Peter O’Donnell Jr. Brain Institute shows that a vaccine delivered to the skin prompts an immune response that reduces buildup of harmful tau and beta-amyloid – without triggering severe brain swelling that earlier antibody treatments caused in some patients.
“This study is the culmination of a decade of research that has repeatedly demonstrated that this vaccine can effectively and safely target in animal models what we think may cause Alzheimer’s disease,” said Dr. Roger Rosenberg, founding Director of the Alzheimer’s Disease Center at UT Southwestern. “I believe we’re getting close to testing this therapy in people.”
The research published in Alzheimer’s Research and Therapy demonstrates how a vaccine containing DNA coding for a segment of beta-amyloid also reduces tau in mice modeled to have Alzheimer’s disease. In addition, the vaccine elicits a different immune response that may be safe for humans. Two previous studies from Dr. Rosenberg’s lab showed similar immune responses in rabbits and monkeys.
================================================
This could be a major breakthrough in treating this disease.
One major pharma company - Pfizer - closed down a small molecule approach research effort recently. They were looking for an inhibitor for the enzyme that produces the amyloid proteins that interfere with normal brain function. I worked on that project, selling a raw material for the proposed drug candidate to their purchasing department in Kalamazoo, MI.
An effective agent for halting or slowing the progression of this disease would be a commercial mega drug.
DALLAS – Nov. 20, 2018 – A DNA vaccine tested in mice reduces accumulation of both types of toxic proteins associated with Alzheimer’s disease, according to research that scientists say may pave the way to a clinical trial.
A new study by UT Southwestern’s Peter O’Donnell Jr. Brain Institute shows that a vaccine delivered to the skin prompts an immune response that reduces buildup of harmful tau and beta-amyloid – without triggering severe brain swelling that earlier antibody treatments caused in some patients.
“This study is the culmination of a decade of research that has repeatedly demonstrated that this vaccine can effectively and safely target in animal models what we think may cause Alzheimer’s disease,” said Dr. Roger Rosenberg, founding Director of the Alzheimer’s Disease Center at UT Southwestern. “I believe we’re getting close to testing this therapy in people.”
The research published in Alzheimer’s Research and Therapy demonstrates how a vaccine containing DNA coding for a segment of beta-amyloid also reduces tau in mice modeled to have Alzheimer’s disease. In addition, the vaccine elicits a different immune response that may be safe for humans. Two previous studies from Dr. Rosenberg’s lab showed similar immune responses in rabbits and monkeys.
================================================
This could be a major breakthrough in treating this disease.
One major pharma company - Pfizer - closed down a small molecule approach research effort recently. They were looking for an inhibitor for the enzyme that produces the amyloid proteins that interfere with normal brain function. I worked on that project, selling a raw material for the proposed drug candidate to their purchasing department in Kalamazoo, MI.
An effective agent for halting or slowing the progression of this disease would be a commercial mega drug.
Last edited:
